Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion

FGFR inhibitors, including pemigatinib, have shown promise in the management of CCA with FGFR2 fusion or rearrangement; however, acquired resistance remains a major barrier in the field of FGFR inhibitors and requires further study.